Enterprise Value
-65.06M
Cash
143.8M
Avg Qtr Burn
-12.15M
Short % of Float
0.17%
Insider Ownership
10.59%
Institutional Own.
9.56%
Qtr Updated
12/31/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ADG116 (CTLA4) Details Solid tumor/s, Cancer | Phase 1/2 Data readout | |
ADG126 (CTLA4) + Pembrolizumab Details Solid tumor/s, Cancer | Phase 1/2 Data readout | |
ADG106 (CD137) Details Solid tumor/s, Cancer, Non-small cell lung carcinoma, Breast cancer, ER+/HER2- breast cancer | Failed Discontinued |